IceCure Medical (NASDAQ:ICCM – Get Free Report) is projected to release its Q3 2026 results before the market opens on Wednesday, November 18th. Analysts expect IceCure Medical to post earnings of ($0.83) per share and revenue of $0.88 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 18, 2026 at 10:00 AM ET.
IceCure Medical (NASDAQ:ICCM – Get Free Report) last released its earnings results on Tuesday, June 30th. The company reported ($1.60) EPS for the quarter. IceCure Medical had a negative return on equity of 174.26% and a negative net margin of 427.67%. The company had revenue of $0.91 million during the quarter. On average, analysts expect IceCure Medical to post ($4.61) EPS for the current fiscal year and ($3.61) EPS for the next fiscal year.
IceCure Medical Price Performance
NASDAQ ICCM opened at $0.79 on Wednesday. IceCure Medical has a 12 month low of $0.65 and a 12 month high of $22.50. The stock’s fifty day moving average price is $1.44 and its 200-day moving average price is $7.37.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on the stock. Zacks Research upgraded shares of IceCure Medical from a “strong sell” rating to a “hold” rating in a research note on Monday, October 12th. Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a research note on Thursday, October 15th. Finally, Wall Street Zen lowered shares of IceCure Medical from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $30.00.
Check Out Our Latest Stock Analysis on IceCure Medical
IceCure Medical Company Profile
IceCure Medical Ltd. is an Israel-based medical technology company focused on minimally invasive cryoablation treatments for cancerous and benign tumors. Its technology uses extremely cold temperatures, generated by liquid nitrogen, to destroy targeted tissue while limiting damage to surrounding areas. The company’s primary product is the ProSense Cryoablation System, which consists of a console, cryoprobes and related components. The system is designed to freeze and ablate tumors through a percutaneous procedure, generally under image guidance.
Read More
- Five stocks we like better than IceCure Medical
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
